Severity of liver disease affects HCV kinetics in patients treated with intravenous silibinin monotherapy
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics; Loyola Univ. Medical Center, Maywood, IL (United States). Division of Hepatology, Dept. of Medicine; Univ. of Edinburgh, Scotland (United Kingdom)
- Loyola Univ. Medical Center, Maywood, IL (United States). Division of Hepatology, Dept. of Medicine; Univ. of South Carolina-Beaufort, Bluffton, SC (United States)
- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona (Spain)
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics
- Biomedical Research Networking Center in Hepatic and Digestive Diseases (CIBEREHD) and August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona (Spain)
- Rottapharm, Monza (Italy)
- Medical Univ. of Vienna, Vienna (Austria). Dept. of Gastroenterology and Hepatology
- Loyola Univ. Medical Center, Maywood, IL (United States). Division of Hepatology, Dept. of Medicine
- Los Alamos National Lab. (LANL), Los Alamos, NM (United States). Theoretical Biology and Biophysics; Loyola Univ. Medical Center, Maywood, IL (United States). Division of Hepatology, Dept. of Medicine
HCV kinetic analysis and modeling during antiviral therapy have not been performed in decompensated cirrhotic patients awaiting liver transplantation. Here, viral and host parameters were compared in patients treated with daily intravenous silibinin (SIL) monotherapy for 7 days according to the severity of their liver disease. Data were obtained from 25 patients, 12 non-cirrhotic, 8 with compensated cirrhosis and 5 with decompensated cirrhosis. The standard-biphasic model with time-varying SIL effectiveness (from 0 to εmax) was fit to viral kinetic data. Our results show that baseline viral load and age were significantly associated with the severity of liver disease (p<0.0001). A biphasic viral decline was observed in most patients with a higher first phase decline patients with less severe liver disease. The maximal effectiveness, εmax, was significantly (p≤0.032) associated with increasing severity of liver disease (εmax[s.e.]=0.86[0.05], εmax=0.69[0.06] and εmax=0.59[0.1]). The 2nd phase decline slope was not significantly different among groups (mean 1.88±0.15 log10IU/ml/wk, p=0.75) as was the rate of change of SIL effectiveness (k=2.12/day[standard error, SE=0.18/day]). HCV-infected cell loss rate (δ[SE]=0.62/day[0.05/day]) was high and similar among groups. We conclude that the high loss rate of HCV-infected cells suggests that sufficient dose and duration of SIL might achieve viral suppression in advanced liver disease.
- Research Organization:
- Los Alamos National Laboratory (LANL), Los Alamos, NM (United States)
- Sponsoring Organization:
- USDOE; National Institutes of Health (NIH)
- Grant/Contract Number:
- AC52-06NA25396; R01-AI07881; P20-GM103452; R01-AI028433; R01-OD011095
- OSTI ID:
- 1282059
- Journal Information:
- Antiviral Therapy, Vol. 20, Issue 2; ISSN 1359-6535
- Publisher:
- International Medical PressCopyright Statement
- Country of Publication:
- United States
- Language:
- English
Web of Science
Early HCV viral kinetics under DAAs may optimize duration of therapy in patients with compensated cirrhosis
|
journal | December 2018 |
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial
|
journal | April 2020 |
Modeling suggests that microliter volumes of contaminated blood caused an outbreak of hepatitis C during computerized tomography
|
journal | January 2019 |
Ombitasvir/Paritaprevir/Ritonavir & Dasabuvir ± Ribavirin following protease inhibitors failure - A Prospective Multi-Centre Trial
|
posted_content | April 2020 |
Similar Records
Sustained virological response with intravenous silibinin: individualized IFN-free therapy via real-time modelling of HCV kinetics
A Hepatitis C Virus Infection Model with Time-Varying Drug Effectiveness: Solution and Analysis